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Abstract
Background: Classic congenital adrenal hyperplasia (CAH) requires lifetime steroid replacement and
supraphysiologic glucocorticoid dose is often required for adequate adrenal androgen suppression. Patients
often suffer from long-term co-morbidities and female infertility is common.
Case presentation: We report the use of laparoscopic bilateral adrenalectomy as a treatment for a 21 year
old female with classic simple virilizing CAH and infertility. She presented as an adolescent with increasing
weight gain, amenorrhea and elevated adrenal androgens despite the use of dexamethasone (250 mcg given
twice daily), and fludrocortisone (150 mcg daily). An anti-androgen (flutamide 250 mg given twice daily) and
a combined oral contraceptive pill were added to her regimen and prevented progressive virilization, but she
eventually desired fertility. A bilateral laparoscopic adrenalectomy was performed at age 21. The right adrenal
gland weighed 41.8 grams and the left gland 45.5 grams. There were no complications during the surgery.
Since the surgery, she has had a total of three pregnancies, resulting in 3 healthy full-term infants. Follow-up
7 years later at age 27 revealed overall excellent health with a BMI of 25.1 kg/m2, no evidence of adrenal rest
tissue based on hormonal testing, above average quality-of-life based on 36-item short-form health survey
and she has not experienced an adrenal crisis.
Conclusions: This case highlights the use of bilateral adrenalectomy as a treatment option for female
infertility in a patient with classic CAH and difficult-to-control hyperandrogenism secondary to adrenal nodular
hyperplasia. Outstanding quality-of-life, disease control and fertility were achieved.
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Background
Classic congenital adrenal hyperplasia (CAH) is an
autosomal recessive disease of adrenal steroidogenesis
due to mutations of the CYP21A2 gene, which encodes
the 21-hydroxylase (21-OH) enzyme. 21-OH deficiency
results in impaired glucocorticoid and mineralocorticoid
production and androgen excess. Clinically, the most se-
vere form of CAH is classified as classic and the milder
form is known as non-classic. Within the classic form
there are sub-classifications that relate to the degree of
aldosterone deficiency. These range from the salt-wasting
(SW) to the simple virilizing (SV) forms, with good
genotype-phenotype correlation [1]. Overproduction and
accumulation of cortisol precursors, such as 17-
hydroxyprogesterone (17-OHP) and androstenedione, oc-
curs and these precursors are shunted into the androgen
synthesis pathway resulting in androgen excess [1]. The
increased androgen secretion in CAH also results in an
increase in progesterone during the follicular phase of
the menstrual cycle that can lead to irregular menses,
amenorrhea and/or infertility [2, 3].
All patients with classic CAH require glucocorticoid
and mineralocorticoid replacement therapy. Optimal
therapeutic regimens are difficult to achieve. Children
are treated with the short-acting glucocorticoid, hydro-
cortisone, but various glucocorticoid regimens are used
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for adults. At the National Institutes of Health (NIH)
Clinical Center, approximately one-third of adults receive
hydrocortisone, one-third receive prednisone and one-third
receive dexamethasone [4]. Similarly, Arlt et al. reported a
cohort of 203 adult patients in the United Kingdom and
found that females with classic CAH received prednisolone
(48 %), dexamethasone (17 %) or hydrocortisone (20 %) [5].
Glucocorticoid treatment is meant to replace cortisol
as well as suppress the hypothalamic-pituitary-adrenal
axis to prevent adrenal hyperplasia and adrenal overpro-
duction of androgens. The use of glucocorticoids in the
management of classic CAH has been lifesaving, but
in many patients it can be difficult to adequately suppress
excess androgens without causing hypercortisolism and
cushingoid features. It is far more difficult to suppress
adrenal androgen production than to prevent adrenal
crises and patients often suffer from both glucocorticoid
and androgen excess [6].
Although adrenalectomy as a treatment option for
CAH has been proposed, it has only been performed in
select cases [7]. At the NIH over 350 patients with CAH
are being followed in a Natural History Study [4]. Two
female patients have undergone adrenalectomy, one pre-
viously reported [7]. We report here our second case, a
21 year old female with classic SV CAH and refractory
hyperandrogenism. She was treated with dexamethasone,
fludrocortisone, an antiandrogen and oral contraceptive,
and subsequently underwent bilateral laparoscopic adre-
nalectomy because of desired fertility.
Case presentation
Our patient was diagnosed with CAH at age two when
she presented with clitoromegaly and increased growth
velocity with a bone age of 5 years 6 months. Genetic
testing confirmed the diagnosis of classic SV CAH
(p.I172N, CYP21A2 30 kb deletion). She underwent clit-
oral reduction and vaginoplasty to correct a urogenital
sinus. She first came to NIH at age 5, and showed a pat-
tern of poor disease control as an adolescent. She had me-
narche at age 14 with subsequent secondary amenorrhea
from age 15. Her weight fluctuated with BMI ranging
from 22 to 29 kg/m2. She had consistently high laboratory
values with a 17-OHP peaking at 52,900 ng/dL. Signs of
virilization were controlled with the use of dexamethasone
(250 mcg given twice daily), fludrocortisone (150 mcg
daily), flutamide (250 mg given twice daily) and a
combined oral contraceptive pill. These medications were
well tolerated, liver function tests were monitored and
remained normal; however, regular menses did not
resume. At age 19, she married and desired fertility.
Although virilization did not progress while receiving
flutamide, androgen levels remained elevated (total
testosterone range 160 – 283 ng/dL; normal 8 – 60 ng/dL)
and could not be adequately suppressed without inducing
significant cushingoid effects. Adrenal computerized
tomography scan showed bilateral moderately hyperplastic
adrenals with a left adrenal gland nodule (Fig. 1a). Bilateral
adrenalectomy was considered as her androgens became







Fig. 1 a Adrenal computerized tomography scan shows bilateral adrenal hyperplasia with a left adrenal gland nodule (arrow). b Hypertrophied
right adrenal gland (weight 41.8 grams, normal adrenal weight 4 – 6 grams). c Histopathology of the classic simple virilizing CAH adrenal shows
preservation of the adrenal cortex zonation (ZG, zona glomerulosa; ZF, zona fasciculata; ZR, zona reticularis) and the inner medulla (M) (d) Histology of
a healthy unaffected adrenal gland shows the outer cortex with characteristic zones (Hematoxylin and eosin stain, magnification 4X)
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regarding fertility and a desire to start a family. A Bioeth-
ics consult was obtained and the pros and cons of bilateral
adrenalectomy were discussed with the patient and her
family independent of the primary team. The procedure
was approved by the Eunice Kennedy Shriver National
Institute of Child Health and Human Development
Institutional Review Board. Written informed consent
was obtained under the Natural History Study of Excess
Androgen (NCT00250159, https://clinicaltrials.gov/ct2/
show/NCT00250159).
A bilateral laparoscopic adrenalectomy was performed
at age 21. The right adrenal gland weighed 41.8 grams
(Fig. 1b) and the left gland 45.5 grams (normal adrenal
gland weight 4 – 6 grams) (Fig. 1c). Her adrenal glands,
despite generalized hypertrophy, maintained zonation
with a small area of distinct medulla (Fig. 1d), consistent
with her SV genotype. The patient was given 100 mg of
intravenous hydrocortisone preoperatively and received
stress doses of hydrocortisone for 2 days. Beginning on
post-operative day 3, she was treated with hydrocorti-
sone 20 mg in the morning and 10 mg in the evening
and 100 mcg of fludrocortisone daily. On post-operative
day 8, adrenal steroids (17-OHP, androstenedione and
testosterone) were undetectable. She had a reduction of
the evening dose of hydrocortisone to 5 mg in 6 weeks
and was treated with an oral contraceptive for 10 months.
After cessation of the oral contraceptive she became
pregnant within 6 months. Since the surgery, she has
had a total of 3 pregnancies, all within 6 months of try-
ing to conceive. All three children were full-term,
healthy and screened negative for CAH by hormonal
testing. Follow-up 6 years later at age 27 revealed over-
all excellent health with a BMI of 25.1 kg/m2, no evi-
dence of adrenal rest tissue based on hormonal testing,
and above average quality-of-life on the 36-item short-
form health survey (norm based scores across all eight
domains on the 36 item short-form health survey
ranged from 55.3 to 63.3, above the general population
mean of 50). Since her adrenalectomy, she has not ex-
perienced an adrenal crisis.
Discussion
Our case highlights the disease related morbidities and sig-
nificant challenges of managing adult females with classic
CAH. Our patient’s weight loss, lack of adrenal crisis and
improved quality-of-life 7 years after surgery supports
adrenalectomy as a therapeutic option in select cases, and
especially in the treatment of female infertility. Suboptimal
response to medical management of her CAH and a strong
desire for fertility led to the consideration of surgery.
Our patient suffered from a combination of glucocortic-
oid excess and hyperandrogenism during adolescence.
Her course was complicated by poor compliance, a com-
mon occurrence in adolescents with a chronic condition
requiring daily medication [8, 9]. Management of adoles-
cents with classic CAH is particularly challenging and fo-
cuses on control of androgen excess while avoiding
cushingoid side effects of overtreatment. Prevention of
long-term adverse outcomes, such as suboptimal sexual
health, infertility and tumor formation, is of utmost
importance [8]. Adrenal hyperplasia, nodularity and tumor
formation occur with long-standing poorly controlled dis-
ease and if not prevented can complicate disease manage-
ment, as seen with our patient presented here.
The desire to avoid high dose glucocorticoids in order
to achieve adrenal androgen suppression led to our use
of the anti-androgen flutamide and a combined oral
contraceptive pill. The use of this therapeutic approach
to control the signs and symptoms of hyperandrogenism
was successful, but the long-term success of this therapy
is unknown because our patient eventually desired fertility.
To address the androgen excess feature of CAH, peripheral
blockade of androgens and androgen synthesis inhibitors
have been used in clinical trials in prepubertal children
with classic CAH and in a phase 1 study of adult women
with classic CAH respectively, but this approach is not
considered standard therapy [10, 11]. However, the use of
an oral contraceptive and the antiandrogen spironolactone
is commonly used in the treatment of non-classic CAH,
the mild form of the disease [12]. We did not use spirono-
lactone in this patient with classic CAH due to the diuretic
effect of spironolactone and because it is a weaker anti-
androgen than flutamide. Flutamide acts to inhibit andro-
gen activity and oral contraceptives are protective of the
ovaries from becoming polycystic and androgen secreting.
A study of flutamide administration in 8 patients with
polycystic ovary syndrome showed an improvement in
hirsutism, a decrease in androgen levels and a reduction in
ovarian volume possibly due to flutamide’s effects on
androgen biosynthesis in ovarian theca cells [13].
Adrenalectomy has been considered as a prophylactic
treatment option for classic CAH [7, 14], but our case does
not support this approach. A long term study of a 3 year
old with SW CAH due to a double null mutation in
CYP21A2 who underwent prophylactic adrenalectomy re-
vealed normal growth and development due to manage-
ment with lower dose glucocorticoid replacement post
adrenalectomy [15]. But caution should be used because
genotype does not always predict adult phenotype [16]. Pa-
tients with salt-wasting CAH may do well as adults, while
patients with simple virilizing CAH, such as the patient de-
scribed here, may suffer from multiple co-morbidities. The
distinction between SW and SV, although sometimes use-
ful in the management of young children, may be unim-
portant in the management of adults with classic CAH
[17]. Our patient is an example of this phenomenon. The
factors that contribute to the development of adult co-
morbidities require further study.
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A common concern regarding adrenalectomy in pa-
tients with CAH is not the surgical procedure itself but
the long-term risks following removal of the adrenals.
Most important is the concern regarding the mortality
risk and the potential protective function of the adrenals
in CAH, which when stressed may produce small
amounts of cortisol. There is also an observed decrease
in blood pressure after adrenalectomy which may reflect
a loss of mineralocorticoid protective effects against
volume depletion [17]. In SW CAH, the adrenal glands
are unable to produce sufficient amounts of cortisol and
epinephrine and thus surgical removal of the adrenal
glands most likely does not increase the risk of an adrenal
crisis [18]. However, our patient had SV CAH and there-
fore would be expected to have some endogenous cortisol
and epinephrine secretion. Indeed, her adrenal glands,
despite generalized hypertrophy, maintained zonation
with a small area of distinct medulla. Despite having a less
severe genetic mutation and less developmental impair-
ment of the adrenal gland, several years of noncompliance
induced adrenal hypertrophy leading to a state of excess
adrenal androgen production which was difficult to con-
trol with medical management alone.
The outcome after surgery with respect to quality-of-
life, disease control and fertility indicates that bilateral
adrenalectomy was a positive therapeutic option for our
patient. Similarly, Ogilvie et al. reported two females with
classic CAH who underwent adrenalectomy for infertility
and became pregnant within 2 years [19].
Our patient continues on hydrocortisone and fludro-
cortisone replacement and is being followed annually.
Given that our patient is doing well on glucocorticoid
and mineralocorticoid replacement, we have not consid-
ered dehydroepiandrosterone (DHEA) supplementation,
which would only be considered if she were to develop
low libido, depressive symptoms or low energy despite
optimized glucocorticoid and mineralocorticoid replace-
ment [20]. In addition to monitoring glucocorticoid re-
placement based on clinical assessment, management
includes measuring 17-OHP and androstenedione levels
for evidence of adrenal rest tissue and measurement of
plasma renin activity to assess mineralocorticoid replace-
ment. A review of 18 cases of patient with CAH who had
undergone adrenalectomy revealed that approximately
one-third of patients had evidence of adrenal rest tissue
activation following adrenalectomy leading to increased
dosing of glucocorticoid replacement [7]. As suggested in
the recent Endocrine Society Clinical Practice Guideline
for management of primary adrenal insufficiency, meas-
urement of ACTH to guide glucocorticoid replacement is
not recommended [20].
Many patients who might be considered for adrenalec-
tomy due to uncontrolled hyperandrogenism have a his-
tory of noncompliance, as seen in our patient. This habit
of non-compliance must be carefully addressed prior to
surgery and monitored after surgery because of the risk of
experiencing a life-threatening adrenal crisis. Informed
consent and patient education with a discussion of poten-
tial risks is essential. Close monitoring is warranted.
Conclusions
The manifestations of classic CAH in adulthood are greatly
influenced by disease control, prior therapy and compliance
and acquired co-morbidities. Bilateral laproscopic adrenal-
ectomy is not commonly performed as a therapeutic option
for CAH. Concerns include surgical risk, loss of protective
adrenal function and risk of recurrent virilization due to ad-
renal rest [12]. However, bilateral adrenalectomy was suc-
cessful for our patient with classic SV CAH and may be
considered as a treatment option for female patients with
classic CAH with difficult to control hyperandrogenism, ad-
renal nodular hyperplasia and infertility.
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